Abstract
Background
Pancreatic neuroendocrine tumors (PNET) locally advanced may lead to significant local symptoms especially segmental portal hypertension (SPH) with risk of bleeding. The aim of our study was to evaluate the role of SPH on the PNET management in an expert center.
Methods
Forty-two patients treated for locally advanced PNET with SPH between January 1984 and December 2012 were retrospectively analyzed.
Results
The median age was 55 years (25–75). The median tumor size was 7.5 cm (3–20). Thirty four (80.9 %) patients were metastatic mainly in the liver (n = 33, 79 %) with a frequent (n = 16, 38.1 %) involvement >20 %. The surgery was impossible because of SPH in 7 (16.6 %) cases. Pancreatic resection was performed in 28 (66.7 %) cases by distal pancreatectomy. Neoadjuvant chemotherapy (n = 24, 57 %) had no impact on SPH with no modification of collateral circulation. Among operated on patients, complete macroscopic resection was obtained in 19 (67.8 %) patients. The mortality and severe morbidity rate was respectively 3.6 and 18 %. Five year overall survival (OS) was similar in operated and no operated patients. (61 %; p = 0.64). The 5-year OS was 77.9 or 55.4 % in patients who underwent a complete or incomplete macroscopic resection of primary and metastases, respectively.
Conclusion
PNET resection associated with SPH is feasible with a low morbimortality. SPH was not improved by chemotherapy. Prolonged survival was observed after complete macroscopic resection.
Similar content being viewed by others
References
Franko J, Feng W, Yip L, Genovese E, Moser AJ (2010) Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2158 patients. J Gastrointest Surg 14:541–548
Strosberg JR, Cheema A, Weber J, Han G, Coppola D, Kvols LK (2011) Prognostic validity of a novel American Joint Committee on cancer staging classification for pancreatic neuroendocrine tumors. J Clin Oncol 29:3044–3049
Evans DB, Skibber JM, Lee JE et al (1993) Nonfunctioning islet cell carcinoma of the pancreas. Surgery 114:1175–1181
Solorzano CC, Lee JE, Pisters PW et al (2001) Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 130:1078–1085
Hellman P, Andersson M, Rastad J et al (2000) Surgical strategy for large or malignant endocrine pancreatic tumors. World J Surg 24:1353–1360. doi:10.1007/s002680010224
Koklu S, Coban S, Yuksel O, Arhan M (2007) Left-sided portal hypertension. Dig Dis Sci 52:1141–1149
Shah SA, Amarapurkar AD, Prabhu SR, Kumar V, Gangurde GK, Joshi RM (2010) Splenic mass and isolated gastric varices: a rare presentation of a neuroendocrine tumor of the pancreas. JOP 11:444–445
Joyce DL, Hong K, Fishman EK, Wisell J, Pawlik TM (2008) Multi-visceral resection of pancreatic VIPoma in a patient with sinistral portal hypertension. World J Surg Oncol 28:6–80
Singhal D, Kakodkar R, Soin AS, Gupta S, Nundy S (2006) Sinistral portal hypertension—a case report. JOP 7:670–673
Watase M, Sakon M, Monden M et al (1992) A case of splenic vein occlusion caused by the intravenous tumor thrombus of nonfunctioning islet cell carcinoma. Surg Today 22:62–65
Wang H, Bie P, Zhang L (2011) Refractory gastroesophageal variceal bleeding secondary to neuroendocrine carcinoma in the pancreatic tail. Pancreatology 11:228–232
Falconi M, Bartsch DK, Eriksson B et al (2012) ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well differentiated pancreatic non-functionning tumors. Neuroendocrinology 95:120–134
Rindi G, Kloppel G, Alhman H et al (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449:395–401
Elias D, Goere D, Leroux G et al (2009) Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liver. Eur J Surg Oncol 35:1092–1097
Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213
Bassi C, Dervenis C, Butturini G et al (2005) Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 138:8–13
Abu Hilal M, McPhail MJ, Zeidan BA, Jones CE, Johnson CD, Pearce NW (2009) Aggressive multi-visceral pancreatic resections for locally advanced neuroendocrine tumours. Is it worth it? JOP 10:276–279
Sarmiento JM, Que FG, Grant CS, Thompson GB, Farnell MB, Nagorney DM (2002) Concurrent resections of pancreatic islet cell cancers with synchronous hepatic metastases: outcomes of an aggressive approach. Surgery 132:976–982
Metairie S, Azoulay D, Castaing D (2003) Portal collateral circulation and pancreatic carcinoma: bypass the obstacle. Gastroenterol Clin Biol 27:923–926
Norton JA, Kivlen M, Li M, Schneider D, Chuter T, Jensen RT (2003) Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg 138:859–866
Teh SH, Deveney C, Sheppard BC (2007) Aggressive pancreatic resection for primary pancreatic neuroendocrine tumor: is it justifiable? Am J Surg 193:610–613
Sasson AR, Hoffman JP, Ross EA, Kagan SA, Pingpank JF, Eisenberg BL (2002) En bloc resection for locally advanced cancer of the pancreas: is it worthwhile? J Gastrointest Surg 6:147–157
Grutzmann R, Ruckert F, Hippe-Davies N, Distler M, Saeger HD (2012) Evaluation of the International Study Group of Pancreatic Surgery definition of post-pancreatectomy hemorrhage in a high-volume center. Surgery 151:612–620
Hung JS, Chang MC, Lee PH, Tien YW (2007) Is surgery indicated for patients with symptomatic nonfunctioning pancreatic neuroendocrine tumor and unresectable hepatic metastases? World J Surg 31:2392–2397. doi:10.1007/s00268-007-9264-3
Bernades P, Baetz A, Levy P, Belghiti J, Menu Y, Fekete F (1992) Splenic and portal venous obstruction in chronic pancreatitis—a prospective longitudinal study of a medical-surgical series of 266 patients. Dig Dis Sci 37:340–346
Heider TR, Azeem S, Galanko JA, Behrns KE (2004) The natural history of pancreatitis-induced splenic vein thrombosis. Ann Surg 239:876–880
Loftus JP, Nagorney DM, Ilstrup D, Kunselman AR (1993) Sinistral portal hypertension—splenectomy or expectant management. Ann Surg 217:35–40
Delaunoit T, Ducreux M, Boige V et al (2004) The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? Eur J Cancer 40:515–520
Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D (1992) Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519–523
Kouvaraki MA, Ajani JA, Hoff P et al (2004) Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22:4762–4771
Strosberg JR, Fine RL, Choi J et al (2011) First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117:268–275
Comerota AJ (2012) The future of deep veinous thrombosis and post-thrombotic syndrome in 2020. Phlebology 27:95–102
Elias D, Lefevre JH, Duvillard P et al (2010) Hepatic metastases from neuroendocrine tumors wuth a “thin slice” pathological examination. Ann Surg 251:307–310
Leboulleux S, Dromain C, Vataire AL et al (2008) Prediction and diagnosis of bone metastases in well-differentiated gastro-entero-pancreatic endocrine cancer: a prospective comparison of whole body magnetic resonance imaging and somatostatin receptor scintigraphy. J Clin Endocrinol Metab 93:3021–3028
Acknowledgments
The authors acknowledge Pr Antonio Sa Cunha (Paul Brousse Hospital—Paris XI University—Villejuif—France).
Conflict of interest
The authors have no conflicts of interest and source of funding. The subject of study had no commercial interest, no financial or material support.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dumont, F., Goudard, Y., Caramella, C. et al. Therapeutic Strategies for Advanced Pancreatic Neuroendocrine Tumors with Segmental Portal Hypertension. World J Surg 39, 1974–1980 (2015). https://doi.org/10.1007/s00268-015-3030-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00268-015-3030-8